In 2017, ADV7103 was granted orphan drug designation by the European Commission in the treatment of distal renal tubular acidosis (dRTA), a rare kidney disorder that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood. Currently in Phase III clinical trials for this indication in Europe, the United States and Canada, ADV7103 was submitted for European marketing authorization in March of 2019. If approved, it will be the first authorized treatment for dRTA.
While we prepare its European commercial launch for dRTA, we are simultaneously conducting trials for ADV7103 in the treatment of cystinuria, a genetic disease characterized by cystine stones in the kidneys and bladder.
ADV7103’s Phase II/III European clinical trials for cystinuria were recently expanded to Belgium.
Headquartered in Nîmes, France, Advicenne was listed on the Euronext Paris stock exchange in December 2017 (ADVIC – FR0013296746). In June 2019, shares of our company began trading on the Euronext Brussels, giving Advicenne cross-listed status on the two largest Euronext life sciences markets.
At Advicenne, we are committed to innovating in the areas of formulation and clinical development. Tasteless and easy to administer, ADV7103 will be commercialized in small-size formats that offer flexible, personalized dosing – because pathbreaking treatments for rare diseases should be available to patients of all ages.
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2020 Advicenne